ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Impact of SGLT2 Inhibitors on Tumor Development Risk in Type 2 Diabetes: A Retrospective Cohort Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Diabetes and cancer: glucose control impact on survival and tumor outcomes.Reviews in endocrine & metabolic disorders · 2026Review
- α-Klotho as a central integrative signalling hub in cognitive function and neuroprotection in neurodegenerative diseases.Metabolic brain disease · 2026Review
- Metabolic reprogramming in diabetes and cancer: the role of PI3K/AKT/mTOR and beyond.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the association between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and the risk of tumor development and survival outcomes in patients with type 2 diabetes. Methods: This retrospective cohort study included 350 patients with type 2 diabetes treated at our institution between January 2021 and January 2025. Patients were categorized into an observation group (n = 189) receiving SGLT2 inhibitors and a control group (n = 161) treated with other antidiabetic medications. Clinical characteristics, glycemic control, cumulative drug exposure, and tumor incidence (lung, colorectal, prostate, breast, bladder, and hepatic cancers) were analyzed. Kaplan-Meier methods were used to evaluate cancer incidence and mortality outcomes. Results: Overall tumor incidence was significantly lower in the SGLT2 inhibitor group than in the control group (P < 0.001), mainly due to reduced lung (P = 0.018) and ovarian cancers (P = 0.017). Smoking, alcohol consumption, and poor glycemic control were associated with higher overall and site-specific tumor risks. The SGLT2 inhibitor group showed better metabolic profiles, with lower FBG, HbA1c, LDL, TC, TG, and higher HDL levels (all P < 0.05), as well as improved renal function indicated by lower BUN and creatinine and higher eGFR (all P < 0.001). Kaplan-Meier analysis demonstrated significantly longer progression-free and overall survival in the SGLT2 inhibitor group (both P < 0.01). Conclusion: SGLT2 inhibitors reduced overall tumor risk, especially lung and ovarian cancers, and improved metabolic and survival outcomes in type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.